Poly (ADP ribose) polymerase (PARP) inhibitor combinations are currently being developed as a treatment strategy for advanced cancers with partial, potential, or no known DNA repair deficits in order to augment the anti-cancer potential of both the PARP inhibitor and the chemotherapy partner. The phase III development of PARP inhibitors in ovarian cancer has focused on single agents. As such, PARP inhibitors have demonstrated their greatest efficacy in cancers with underlying DNA repair deficits, such as deleterious mutations in BRCA1 or BRCA2, or when used in clinical situations when homologous recombination deficiency (HRD) is operative, such as recently described results for niraparib in platinum-sensitive high-grade serous ovarian cancer [1] [2] [3] [4] . Single-agent PARP inhibitors have less activity in BRCA wildtype, especially platinum resistant, or HR proficient cancers [5] .
In the accompanying phase I trial, Thaker et al. attempt to combine veliparib, a potent oral inhibitor of PARP, with DNA damaging chemotherapy. Working under the umbrella of NRG Oncology, the triplet of cisplatin/paclitaxel/veliparib was studied in women with persistent or recurrent cervical cancer. The rationale for adding the PARP inhibitor veliparib to cisplatin was to augment cisplatin's anti-cancer potential and because PARP-1 expression is higher in cervical cancer cells than in normal cells [6, 7] . Additionally, the complex pathogenesis of cervical cancer and the interaction of PARP, HPV, DNA repair, and inflammation make the study of PARP inhibition in cervical cancer rational [8] . Thaker et al. [6] dose escalated veliparib up to 400 mg BID, the maximal tolerated dose (MTD) for the single agent, and veliparib was administered for 7 days rather than continuously. Response rates for this PARP inhibitor and chemotherapy combination in advanced cervical cancer across all dose levels were 34%, reaching responses of 60% at the highest dose of veliparib tested. During the conduct of this study, the US Food and Drug Administration gave regulatory approval for cisplatin/paclitaxel/bevacizumab for advanced/recurrent cervical cancer [9] , thus making pursuit of cisplatin/paclitaxel/veliparib less compelling for this indication. However, the triplet under study did have a numerically higher overall response rate (ORR) at the MTD compared with the bevacizumab triplet with an identical chemotherapy backbone [6, 9] . Granted, cross trial comparisons with this small PARP inhibitor combination phase I trial are near impossible.
How should PARP inhibitor combinations be selected for development?
Ideally, there should be a predefined understanding of the mechanisms of augmentation of anti-cancer activity of the combination and whether or not additive or synergistic effects are predicted to occur clinically. PARP inhibitors have several known mechanisms of action including inhibition of DNA single strand break (SSB) repair [by inhibiting base excision repair (BER)] leading to double strand breaks (DSB); alteration of non-HR DNA repair pathways, such as promotion of classic non-homologous end joining (classic-NHEJ)-a more error prone mechanism of DNA repair, and disruption of alternative end joining (alt-EJ) which is essential for HR-deficient cells, and PARP trapping; PARP inhibitors trap PARP on DNA, and these PARP-DNA complexes are lethal to HR deficient cells [10] . PARP trapping can induce increased cell killing compared with unrepaired SSBs and also varies amongst PARP inhibitors; veliparib has weaker PARP trapping than olaparib, rucaparib, and niraparib, while talazoparib induces the most potent PARP trapping, though all five agents can potently inhibit PARP catalytic activity [11, 12] . Mechanisms leading to synergy or additive activity of a combined PARP inhibitor and chemotherapy are likely multifactorial and differ based on the combination (i.e. chemotherapy can increase DNA damage, and PARP inhibitors diminish the PARP enzymes ability to repair DNA damage) and tumor studied [7, [13] [14] [15] . The chemotherapy agent and the PARP inhibitor selected for testing will also influence the mechanisms of action of cell death as well as the efficacy of the combination [7, [13] [14] [15] . For example, PARP inhibitor combinations with topoisomerase-I inhibitors such as camptothecin or topotecan are highly synergistic primarily due to catalytic PARP inhibition, suggesting that all PARP inhibitors would be similarly synergistic with topoisomerase-I inhibitors given their potent inhibition of PARP [13, 14] . Conversely, PARP inhibitor combinations with alkylating agents such as temozolomide are highly synergistic due to both catalytic PARP inhibition as well as PARP trapping [14] . In this regard, olaparib is more synergistic with temozolomide compared with veliparib (which has weaker PARP trapping activity). In vitro preclinical assessments show differential cell killing dependent on choice of chemotherapy agent; highest synergism has been reported with topoisomerase-I inhibitors and alkylating agents as stated above, while less synergistic or only additive activity has been observed in vitro with platinum agents (such as cisplatin and carboplatin) and topoisomerase-II inhibitors such as etoposide and doxorubicin which is consistent with the relative lack of involvement of PARP in repair of platinum-and topoisomerase-II inhibitor-induced lesions [15] . Finally, the least combinatorial effect is observed with either a taxane or gemcitabine, although results differ based on experimental conditions [15, 16] .
What are the unique challenges for the development of PARP inhibitor and chemotherapy combinations?
Combinations of PARP inhibitors and chemotherapy agents have unique strategic and development challenges because of overlapping toxicities such as myelosuppression, the array of schedule and drug dosing choices, and potential for drug interactions in humans not identified in pre-clinical models. A major issue with the strategy of enhancing the activity of chemotherapy using PARP inhibitors is its narrow therapeutic window, since the synergism via PARP inhibition is not selective for tumor cells. Rather, inhibition of PARP in normal cells abrogates an important mechanism of DNA repair in these cells thereby enhancing toxicity from chemotherapy including myelosuppression. Choice of drug(s) to be dose escalated should be determined based on planned toxicities such as myelosuppression; Thaker et al. [6] dose escalated only veliparib and kept paclitaxel and cisplatin constant. How was the schedule of 7 days of veliparib (days 1-7) combined with paclitaxel day 1 and cisplatin day 2 determined? Intermittent versus continuous PARP inhibition may have implications on efficacy as well as toxicity. Drew et al. [17] showed that PARP inhibition is short-lived and recovers within 1 week of completion of a 7-day dosing schedule; thus oral continuous dosing is important to maintain in the single agent setting when long-term PARP inhibition is critical to efficacy, with shorter durations leading to reduced myelosuppression but an unknown effect on efficacy. In addition, sequence of agents may also be important for efficacy and tolerability. The phase I study of carboplatin and olaparib led to an MTD of olaparib 200 mg BID for 7 days (tablet formation) and carboplatin AUC 4 [18] . The group from the National Cancer Institute determined that administering carboplatin before olaparib led to faster olaparib clearance due to higher intracellular accumulation of olaparib, thus perhaps predicting greater efficacy [18] . Other phase I studies of combined PARP inhibitors and chemotherapy have been performed showing enhanced myelosuppression (Table 1) ; dose escalation of olaparib/cisplatin/gemcitabine led to lowered doses of all three agents at the MTD: olaparib 100 mg once daily on day 1 only, cisplatin 60 mg/m 2 on day 1 and gemcitabine 500 mg/m 2 day 1 and 8 [19] . Topotecan and veliparib were tested in recurrent cervical cancer, and hematologic toxicities !grade 3 included anemia 59%, thrombocytopenia 44%, and neutropenia 19%, despite the use of myeloid growth factor [20] . Pre-clinical in vitro synergy of topotecan and veliparib was demonstrated and occurred at veliparib combinations below those needed to kill HRD-deficient cells [13] ; however, only 7% response rate was observed when this regimen was tested in recurrent cervical cancer [20] .
Additional PARP inhibitor and chemotherapy combinations have been tested in randomized studies which are critical to determine if the synergy of the combination can overcome the reduced activity of the attenuated doses and prove benefit beyond standard of care [21] (Table 1) . Combined weekly paclitaxel and olaparib was tested in metastatic triple negative breast cancer [22] with significant myelosuppression noted ( Table 1) . This regimen was subsequently tested in a phase 3 study in advanced gastric cancer, and despite encouraging randomized phase 2 data, olaparib and weekly paclitaxel did not improve overall survival nor progression-free survival (PFS) compared with weekly paclitaxel alone [23] . Pre-clinical PARP inhibitor and taxane studies showed little in vitro benefit, perhaps foreshadowing the lack of success of paclitaxel and olaparib combination in advanced gastric cancer [15] . In another randomized study, the paclitaxel/carboplatin/olaparib triplet followed by olaparib maintenance was tested against carboplatin and paclitaxel in platinum sensitive recurrent ovarian cancer [24] demonstrating improved PFS for the olaparib containing arm. The carboplatin dose was dose reduced to AUC 4 and the olaparib dose to 200 mg BID, days 1-10, when combined with chemotherapy. However, this PARP inhibitor/ chemotherapy combination has not been moved forward for further clinical development. Lower doses of chemotherapy have also been tested in combination with PARP inhibitors; Kummar et al. [25] performed a randomized trial of oral cyclophosphamide 50 mg PO daily alone or combined with veliparib 60 mg daily in patients with BRCA mutated recurrent ovarian cancer. Pre-clinically, PARP inhibitors were found to augment DNA damage caused by cyclophosphamide; however, adding the PARP inhibitor to oral cyclophosphamide did not improve ORR nor PFS [25] . In BRCA mutated metastatic breast cancer patients, carboplatin/paclitaxel/veliparib was compared with carboplatin/ paclitaxel, and there was no difference in PFS between two groups [26] ; the chemotherapy in both arms was standard dose but the dose of veliparib was 120 mg BID for 7 days. PARP inhibitor combinations with chemotherapy are a novel, potentially therapeutically promising but challenging strategy used to enhance the anti-cancer effects of both a PARP inhibitor and chemotherapy agents, thus expanding the patient population eligible to receive a PARP inhibitor. However, multiple factors will influence clinical trial design including choice of PARP inhibitor and its pharmacokinetic and pharmacokinetic properties, combination partner(s), goals of combining a PARP inhibitor and chemotherapy, which agent(s) to dose escalate, schedule of agents, patient population and clinical situation as well as a changing drug approval and regulatory landscape-further development of velparib/carboplatin/paclitaxel was complicated by the FDA approval of cisplatin/paclitaxel/bevacizumab. In gaining regulatory approval, the importance of each of the different components of treatment will need to be compared with the combination, with the combination showing superiority [21] . Development of PARP inhibitor/chemotherapy combinations, if pursued, will require strong pre-clinical data to support human clinical trial testing, commitment and patience from investigators, sponsors, and patients given the time needed to sort through these factors, and adaptability because of changing clinical landscapes. 
